Core Viewpoint - Hendi Pharmaceutical (301211) forecasts a significant decline in net profit for 2025, estimating a range of 31 million to 39 million yuan, representing a year-on-year decrease of 57.4% to 66.14% [2] Group 1: Financial Performance - The company anticipates a net profit of 31 million to 39 million yuan for 2025, indicating a substantial decline compared to previous years [2] - The projected decline in net profit is attributed to intensified market competition for its main product, ibuprofen raw materials, and certain specialty raw materials, leading to a decrease in gross margin [2] Group 2: Market Conditions - Increased competition in the market for ibuprofen and specialty raw materials is a key factor contributing to the expected decline in profitability [2] - A reduction in interest income from cash management due to falling interest rates is also impacting the company's financial outlook [2]

Group 1 - Shoukai Co. achieved a signed area of 125.72 million square meters and a signed amount of 17.845 billion yuan in 2025 [1] - Tongda Hai expects a net loss for the year 2025 [2] - Jiuri New Materials' subsidiary has entered the trial production phase for a project with an annual capacity of 350 tons of hydroxy ketone [3] Group 2 - Jixin Technology's shareholder plans to reduce their stake by up to 1% [4] - Fulai New Materials received approval from the CSRC for a stock issuance [5] - Yaqi International plans to sign a strategic cooperation framework agreement with Zhongnong Holdings [6] Group 3 - Sanwei Co.'s controlling shareholder plans to transfer up to 5.10% of shares [7] - Lekai Film's subsidiary plans to invest 97.6675 million yuan in a TAC functional film production line [8] - China Power Construction's subsidiary signed two major contracts totaling approximately 15.589 billion yuan [9] Group 4 - Shunhao Co. plans to increase its investment in a subsidiary by 74.98 million yuan [10] - Jieneng Wind Power reported a cumulative power generation of 12.417 billion kWh in 2025, a year-on-year increase of 1.43% [11] - Zhongjian Technology's H-share issuance application has been accepted by the CSRC [12] Group 5 - Hendi Pharmaceutical expects a net profit decrease of 57.4% to 66.14% in 2025 [13] - Haopeng Technology anticipates a net profit increase of 113.69% to 141.09% in 2025 [14] - Lingang Co. expects a net loss of 1.45 billion to 1.67 billion yuan in 2025 [15] Group 6 - Chuan Investment Energy reported a cumulative power generation of 6.627 billion kWh in 2025, a year-on-year increase of 13.85% [16] - Tengyuan Cobalt expects a net profit increase of 50.02% to 69.87% in 2025 [17] - Huazhi Jie plans to repurchase shares worth 30 million to 50 million yuan [18] Group 7 - Opto has won a bid for a 120 million yuan project from GoerTek [19] - Shanghai Construction reported a new contract amount of 252.942 billion yuan in 2025, a year-on-year decrease of 34.98% [20] - Hangfa Control expects a net profit decrease of 52.02% to 58.02% in 2025 [22] Group 8 - Shimao Energy is planning a change in control and will continue to suspend trading [23] - Shenwan Hongyuan Securities received approval for a bond issuance of up to 60 billion yuan [24] - Jingjiawei signed a strategic cooperation letter of intent with Jing'an Technology [25] Group 9 - Pianzaihuang completed the first subject enrollment for a clinical trial of a new drug [26] - Placo's subsidiary received a new veterinary drug registration certificate [27] - Zhongli Co. plans to reduce its stake by up to 0.75% [28] Group 10 - Solar Energy received renewable energy subsidies of 3.318 billion yuan in 2025, a year-on-year increase of 142.9% [29] - Palm Co. has filed a lawsuit to recover 144 million yuan in project payments [30][31] - Yongjin Co. plans to invest 2.658 billion yuan in a new stainless steel project [32] Group 11 - BAIC Blue Valley plans to increase its stake by 14.5 million to 16.4 million yuan [33] - Lingyun Light's stock issuance application has been approved by the CSRC [34] - Hongbo New Materials expects a net loss in 2025 [35] Group 12 - Shanghai Pharmaceuticals received approval for the listing of a new antifungal drug [36] - Changjiang Electric reported a net profit of 34.167 billion yuan in 2025, a year-on-year increase of 5.14% [37] - Weilan Bio received a new veterinary drug registration certificate [38] Group 13 - Pingzhi Information's subsidiary is expected to win a procurement project worth approximately 37.5884 million yuan [39]

格隆汇1月13日丨亨迪药业(301211.SZ)公布，预计2025年归属于上市公司股东的净利润3,100万元～ 3,900万元，比上年同期下降66.14%～57.40%，扣除非经常性损益后的净利润550万元～820万元，比上 年同期下降92.46%～88.76%。1、由于主产品布洛芬原料药及部分特色原料药产品市场竞争加剧，毛利 率下降。2、现金管理利息收入因利率下降减少。 ...

亨迪药业1月13日公告，预计2025年归母净利润3100万元-3900万元，同比下降66.14%-57.40%。业绩变 动主要由于主产品布洛芬原料药及部分特色原料药产品市场竞争加剧，毛利率下降；现金管理利息收入 因利率下降减少。 ...

证券代码：301211 证券简称：亨迪药业 公告编号：2026-001 湖北亨迪药业股份有限公司 2025 年度业绩预告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重 大遗漏。 公司已就业绩预告有关事项与年报审计会计师事务所进行了预沟通，公司与会计师事 务所在本次业绩预告方面不存在重大分歧。 三、业绩变动原因说明 1、由于主产品布洛芬原料药及部分特色原料药产品市场竞争加剧，毛利率下降。 重要提示： 一、本期业绩预计情况 1、业绩预告期间：2025 年 1 月 1 日至 2025 年 12 月 31 日。 2、业绩预告情况：预计净利润为正值且属于同向下降 50%以上情形 单位：万元 | 项 目 | 本报告期 | | | | 上年同期 | | --- | --- | --- | --- | --- | --- | | 归属于上市公司股 | 比上年同期 | 3,100 | ～ | 3,900 | 9,154.74 | | 东的净利润 | 下降 | 66.14% | ～ | 57.40% | | | 扣除非经常性损益 | 比上年同期 | 550 | ～ | 820 | 7,2 ...

Group 1 - Hendi Pharmaceutical experienced a 5% increase in stock price, reaching 13.65 CNY per share, with a trading volume of 136 million CNY and a turnover rate of 2.41%, resulting in a total market capitalization of 5.7 billion CNY [1] - Hendi Pharmaceutical, established on December 29, 1995, is located in Jingmen City, Hubei Province, and was listed on December 22, 2021. The company specializes in the research, production, and sales of chemical raw materials and formulations [1] - The main revenue composition of Hendi Pharmaceutical includes non-steroidal anti-inflammatory drugs (68.06%), cardiovascular products (16.08%), other products (8.86%), and anti-tumor drugs (6.99%) [1] Group 2 - According to data from the top ten holdings of funds, one fund under Dongfang Fund has a significant position in Hendi Pharmaceutical. The Dongfang Quantitative Multi-Strategy Mixed A Fund (006785) held 11,600 shares in the third quarter, accounting for 0.43% of the fund's net value, ranking as the sixth largest holding [2] - The Dongfang Quantitative Multi-Strategy Mixed A Fund (006785) was established on February 22, 2019, with a latest scale of 28.7844 million CNY. The fund has achieved a year-to-date return of 10.05%, ranking 895 out of 8,836 in its category, and a one-year return of 56.94%, ranking 1,801 out of 8,091 [2] - The fund manager, Wang Huaixun, has been in position for 3 years and 243 days, with the total asset scale of the fund at 799 million CNY. During his tenure, the best fund return was 70.43%, while the worst was -0.06% [2]

湖北亨迪药业股份有限公司 对外捐赠管理制度 湖北亨迪药业股份有限公司 第四条 公司开展对外捐赠事项除遵守国家相关法律、法规及规范性文件的 规定外，还应遵守本制度的相关规定。 第二章 对外捐赠的原则 对外捐赠管理制度 （2025 年 12 月） 第一章 总则 第一条 为依法规范湖北亨迪药业股份有限公司（以下简称"公司"）对外 捐赠行为，防范财务风险，加强公司对捐赠事务的管理，在充分维护股东利益的 基础上，更好地参与社会公益和慈善事业，积极履行社会责任，依据《中华人民 共和国公益事业捐赠法》《中华人民共和国公司法》等法律法规及规范性文件以 及《湖北亨迪药业股份有限公司章程》（以下简称"《公司章程》"）的有关规 定，结合公司的实际情况，制定本制度。 第二条 本制度所称"对外捐赠"，是指公司自愿无偿将其有权处分的合法 财产赠予合法的受赠人，用于与生产经营活动没有直接关系的公益事业的行为。 第三条 本制度适用于公司、全资子公司的对外捐赠事项。未经授权，子公 司不得开展对外捐赠事项。 第五条 自愿无偿原则。公司对外捐赠后，不得要求受赠方在融资、市场准 入、行政许可、占有其他资源等方面创造便利条件，不得以捐赠为名从事营利活 ...

证券代码：301211 证券简称：亨迪药业 公告编号：2025-051 湖北亨迪药业股份有限公司 本公司及董事会全体成员保证公告内容真实、准确、完整，不存 在任何虚假记载、误导性陈述或者重大遗漏。 一、董事会会议召开情况 湖北亨迪药业股份有限公司（以下简称"公司"）第二届董事会第十七次会 议于 2025 年 12 月 23 日以电话及邮件方式送达至全体董事，本次会议于 2025 年 12 月 31 日以现场和通讯方式召开。本次会议应参会董事 8 人，实际参会董 事 8 人。本次会议由公司董事长程志刚主持，公司高级管理人员列席会议。本次 董事会会议的召集、召开和表决程序符合《中华人民共和国公司法》等法律法规 和《公司章程》的有关规定，会议合法、有效。 二、董事会会议审议情况 会议审议并通过了如下议案： 1、审议通过《对外捐赠管理制度》 为规范公司对外捐赠行为，防范财务风险，加强公司对捐赠事务的管理，在 充分维护股东利益的基础上，更好地参与社会公益和慈善事业，积极履行社会责 任，依据《公益事业捐赠法》《公司法》等最新法律法规、规范性文件的要求， 公司结合实际情况，特制定《对外捐赠管理制度》。具体如下： 具体内容详 ...

第一章 总则 第一条 为了规范湖北亨迪药业股份有限公司（以下简称"公司"）互动易 平台信息发布和提问回复的管理，建立公司与投资者良好沟通机制，提升公司治 理水平，根据《上市公司投资者关系管理工作指引》《深圳证券交易所上市公司 自律监管指引第 2 号——创业板上市公司规范运作》等法律、行政法规、部门规 章、规范性文件及《湖北亨迪药业股份有限公司章程》（以下简称"公司章程"） 的规定，制定本制度。 湖北亨迪药业股份有限公司 互动易平台信息发布及回复内部审核制度 （2025 年 12 月） 第五条 公司在互动易平台回复投资者提问时，不得使用虚假性、夸大性、宣 传性、误导性语言，应当注重与投资者交流互动的效果，不得误导投资者。不具 备明确事实依据的，公司不得在互动易平台发布或者回复。 第三章 内容规范性要求 第六条 公司在互动易平台信息发布信息及回复内容应当合法合规，符合以下 要求： （一）不得涉及未公开重大信息。投资者提问涉及已披露事项的，公司可以 对投资者的提问进行充分、详细的说明和答复；涉及或者可能涉及未披露事项的， 公司应当告知投资者关注公司的信息披露公告。公司不得以互动易平台发布或回 复信息等形式代替信息披 ...

证券代码：301211 证券简称：亨迪药业 公告编号：2025-052 湖北亨迪药业股份有限公司董事会 2025 年 12 月 31 日 附件： 代旭勇个人简历 代旭勇，男，1979 年 1 月生，高级工程师，硕士研究生，农工民主党员。 曾任湖北中天亨迪药业有限公司技术部实验员；武汉百科药物开发有限公司技术 部实验员、技术部经理、生产部经理；2013 年 11 月至今任武汉百科药物开发有 限公司副总经理。 代旭勇先生目前未直接持有公司股份，通过荆门市宁康企业管理中心（有限 合伙）间接持有公司 0.135%的股份。与其他持有公司 5%以上股份的股东、实际 控制人、其他董事、高级管理人员不存在关联关系，未受过中国证监会及其他有 关部门的处罚和证券交易所惩戒，不存在作为失信被执行人的情形，任职资格符 合《公司法》及《公司章程》的相关规定，不存在《公司法》第 146 条及《深圳 证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》3.2.3 条规定的情形。 湖北亨迪药业股份有限公司 关于聘任公司总工程师的公告 本公司及董事会全体成员保证公告内容真实、准确、完整，不存 在任何虚假记载、误导性陈述或者重大 ...